Evidence map›Paper›PMID 40572521›Full record

ArticleMolecules (Basel, Switzerland)2025

DFT-Based Elucidation and Evaluation of Selenium-Modified Tacrine Derivatives: Theoretical and Physicochemical Insights for Alzheimer's Disease Therapy.

Roberto Barbosa Morais, Manoela do Sacramento, Cecilia Scimmi, Darling de Andrade Lourenço, Frederico Schmitt Kremer, Lucielli Savegnago, Diego Alves

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Roberto Barbosa MoraisLASOL-CCQFA, Universidade Federal de Pelotas-UFPel, P.O. Box 354-96010-900, Pelotas 96160-000, RS, Brazil.ORCID 0000-0001-8377-3604
Manoela do SacramentoLASOL-CCQFA, Universidade Federal de Pelotas-UFPel, P.O. Box 354-96010-900, Pelotas 96160-000, RS, Brazil.
Cecilia ScimmiGroup of Catalysis, Synthesis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy.ORCID 0009-0009-2194-8670
Darling de Andrade LourençoLaboratório de Bioinformática (Omixlab), Centro de Desenvolvimento Tecnológico (CDTec), Universidade Federal de Pelotas-UFPel, Pelotas 96160-000, RS, Brazil.ORCID 0000-0001-9890-6713
Frederico Schmitt KremerLaboratório de Bioinformática (Omixlab), Centro de Desenvolvimento Tecnológico (CDTec), Universidade Federal de Pelotas-UFPel, Pelotas 96160-000, RS, Brazil.
Lucielli SavegnagoNeurobiotechnology Research Group-GPN, Technological Development Center, Federal University of Pelotas-UFPel, Pelotas 96160-000, RS, Brazil.
Diego AlvesLASOL-CCQFA, Universidade Federal de Pelotas-UFPel, P.O. Box 354-96010-900, Pelotas 96160-000, RS, Brazil.ORCID 0000-0002-1074-0294

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 24/2551-0001949-9 and 23/2551-0001854-3National Council for Scientific and Technological Development 405655/2023-1 and 309498/2023-6
6 · The paper itself

Abstract

The incorporation of selenium into tacrine derivatives has been explored as a novel strategy to enhance therapeutic efficacy while minimizing toxicity in the treatment of neurodegenerative diseases such as Alzheimer's. This study utilized computational and experimental approaches, including Density Functional Theory (DFT), molecular docking, pharmacokinetic profiling, and toxicological predictions, to evaluate the potential of these derivatives. The selenium-modified compounds demonstrated improved electronic properties, such as narrower HOMO-LUMO gaps and optimized electronegativity, resulting in enhanced stability and reactivity. Pharmacokinetic analyses revealed favorable absorption, distribution, and blood-brain barrier penetration, while toxicological assessments indicated reduced hepatotoxicity and skin sensitization risks compared to tacrine. Molecular docking and dynamic simulations highlighted strong and stable interactions of the derivatives with critical enzymes, including acetylcholinesterase (AChE) and beta-secretases (BACE1 and BACE2). Compounds

Indexed as

Alzheimer DiseaseSeleniumTacrineAcetylcholinesteraseAmyloid Precursor Protein SecretasesAnimalsBlood-Brain BarrierCholinesterase InhibitorsDensity Functional TheoryHumansMolecular Docking SimulationMolecular Dynamics SimulationAcetylcholinesteraseAmyloid Precursor Protein SecretasesCholinesterase InhibitorsSeleniumTacrineacetylcholinesterase inhibitorsAlzheimer’s diseasebeta-secretasescomputational drug designdensity functional theorymolecular dockingneurodegenerative diseasespharmacokineticsseleniumtoxicology

Identifiers

PMID40572521
PMCPMC12196396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.